Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate

Drugs in R and D

Volumn 13, Issue 2, 2013, Pages 119-128

  Roesch, Benno ^a   Corcoran, Mary E ^b   Fetterolf, Jennifer ^b   Haffey, Mary ^b   Martin, Patrick ^b   Preston, Peter ^b   Purkayastha, Jaideep ^b   Wang, Phillip ^b   Ermer, James ^b  

^a Advanced Biomedical Research Inc   (United States)

^b SHIRE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMPHETAMINE; GUANFACINE; LISDEXAMFETAMINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED DRUG RELEASE; DIZZINESS; DRUG BLOOD LEVEL; DRUG SAFETY; ECG ABNORMALITY; FEMALE; HEADACHE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; POSITIONAL DIZZINESS; PRIORITY JOURNAL;

ADOLESCENT; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADULT; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; GUANFACINE; HUMANS; MALE; MIDDLE AGED; THERAPEUTIC EQUIVALENCY; VITAL SIGNS;

EID: 84879700298     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.1007/s40268-013-0014-8     Document Type: Article

References (31)

1. Adler LA, Reingold LS, Morrill MS, et al. Combination pharmacotherapy for adult ADHD. Curr Psychiatry Rep. 2006;8(5):409-15. (Pubitemid 44515394)
2. Popper CW. Combining methylphenidate and clonidine: pharmacologic questions and news reports about sudden death. J Child Adolesc Psychopharmacol. 1995;5(3):157-66.
3. Brown TE. Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: four case reports. J Child Adolesc Psychopharmacol. 2004;14(1):129-36. (Pubitemid 38525962)
4. Pohl GM, Van Brunt DL, Ye W, et al. A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD). BMC Health Serv Res. 2009;9:95.
5. Intuniv (package insert). Wayne: Shire Pharmaceuticals Inc.; 2011.
6. Biederman J, Melmed RD, Patel A, et al., for the SPD503 Study Group. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121(1):e73-e84.
7. Sallee F, McGough J, Wigal T, et al., for the SPD503 Study Group. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(2):155-65.
8. Sallee FR, Lyne A, Wigal T, et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(3):215-26.
9. Biederman J, Melmed RD, Patel A, et al. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr. 2008;13(12):1047-55.
10. Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2010;24(9):755-68.
11. Faraone SV, Pucci M, Coghill D. Pharmacotherapy for attention-deficit- hyperactivity disorder. US Psychiatry Rev. 2009;2(1):17-27.
12. Wilens TE, Spencer TJ. Understanding attention-deficit/hyperactivity disorder from childhood to adulthood. Postgrad Med. 2010;122(5):97-109.
13. Vyvanse (package insert). Wayne: Shire US Inc.; 2012.
14. Spencer TJ, Greenbaum M, Ginsberg LD, et al. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(5):501-10.
15. Wilens TE, Youcha S, Lyne A, et al. A multisite placebo-controlled trial of morning or evening dosed extended-release guanfacine in combination with psychostimulants in children and adolescents with ADHD. 65th Annual Meeting of the Society of Biological Psychiatry; 2010 May 20-22; New Orleans.
16. US Department of Health and Human Services. Guidance for industry: in vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072119.pdf. Accessed 26 Oct 2012.
17. Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010;6(1):317-27.
18. Krishnan S, Moncrief S. An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes. Drug Metab Dispos. 2007;35(1):180-4. (Pubitemid 46036490)
19. Boellner SW, Pennick M, Fiske K, et al. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. Pharmacotherapy. 2007;27(9):1253-62. (Pubitemid 47339123)
20. Swearingen D, Pennick M, Shojaei A, et al. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. Clin Ther. 2007;29(4):617-25.
21. Boellner SW, Stark JG, Krishnan S, et al. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study. Clin Ther. 2010;32(2):252-64.
22. Ermer J, Homolka R, Martin P, Purkayastha J, et al. Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers. J Clin Pharmacol. 2010;50(9):1001-10.
23. Krishnan SM, Pennick M, Stark JG. Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. Clin Drug Investig. 2008;28(12):745-55.
24. Krishnan SM, Stark JG. Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. Curr Med Res Opin. 2008;24(1):33-40. (Pubitemid 351160236)
25. Biederman J, Boellner SW, Childress A, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry. 2007;62(9):970-6. (Pubitemid 47562371)
26. Adler LA, Goodman DW, Kollins SH, et al, on behalf of the 303 Study Group. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364-73.
27. Markowitz JS, Patrick KS. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clin Pharmacokinet. 2001;40(10):753-72. (Pubitemid 33027889)
28. Adderall XR (package insert). Wayne: Shire US Inc.; 2010.
29. Bach MV, Coutts RT, Baker GB. Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica. 1999;29(7):719-32. (Pubitemid 29371090)
30. Wilens TE, Spencer TJ. The stimulants revisited. Child Adolesc Psychiatr Clin N Am. 2000;9(3):573-603, viii. (Pubitemid 30620545)
31. Concerta (package insert). Titusville: McNeil Pediatrics; 2010.